Repligen Corporation (RGEN) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
Total Assets Chart for Repligen Corporation
Repligen Corporation (RGEN) total assets for FY2025 were USD 2.9B, a 4.2% change from FY2024. Repligen Corporation's total assets grew from USD 10.3M in 1985 to USD 2.9B in 2025 (28537.9% over 40 years). Total assets compound annual growth rate: 5-year CAGR of 9.2%, 10-year CAGR of 35.0%, 20-year CAGR of 26.1%.
Total Assets (US Dollars)
R&D as % of Revenue
Key Stats
- Market Cap
- $9.87B
- Implied Share Price
- $174.86
- Enterprise Value
- $10.29B
- Revenue (TTM)
- $785.10M
- EBITDA
- $144.10M
- Profit Margin
- 5.29%
- Trailing P/E
- 260.99
- Forward P/E
- 67.11
- Price/Book (MRQ)
- 4.93
- Price/Sales (TTM)
- 12.57
- EV/EBITDA
- 53.61
- EV/Revenue
- 11.72
- Dividend Yield
- —
- Book Value
- $37.43
- Free Cash Flow (FY2025)
- $93.90M
- Free Cash Flow Yield
- 0.95%
Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.